Skip to main
FHTX

Foghorn Therapeutics (FHTX) Stock Forecast & Price Target

Foghorn Therapeutics (FHTX) Analyst Ratings

Based on 6 analyst ratings
Strong Buy
Strong Buy 83%
Buy 17%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Foghorn Therapeutics is positioned to capitalize on the growing interest in precision medicines for cancer treatments, with a seasoned team and strong pre-clinical data for their lead program FHD-909. They have a strategic partnership with Eli Lilly for development and commercialization of their therapies, providing a potential source of revenue and validation of their approach. However, they face competition in the targeted oncology space and must successfully navigate clinical trials and regulatory approvals to achieve success.

Bears say

Foghorn Therapeutics is a clinical-stage biotechnology company with a focus on developing precision therapeutics for serious diseases by targeting the chromatin regulatory system. However, the company carries significant risks due to the reliance on its patent protection for market exclusivity and regulatory approvals for its candidates. Its flagship program, FHD-909, has shown encouraging pre-clinical data, but there are concerns over its selective targeting strategy and potential overlap with other known mutations in NSCLC. Additionally, competition from companies like Arvinas, IDEAYA Biosciences, Kymera Therapeutics, and Nurix Therapeutics further adds to the negative outlook on Foghorn's stock.

Foghorn Therapeutics (FHTX) has been analyzed by 6 analysts, with a consensus rating of Strong Buy. 83% of analysts recommend a Strong Buy, 17% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Foghorn Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Foghorn Therapeutics (FHTX) Forecast

Analysts have given Foghorn Therapeutics (FHTX) a Strong Buy based on their latest research and market trends.

According to 6 analysts, Foghorn Therapeutics (FHTX) has a Strong Buy consensus rating as of Jun 3, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $11.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $11.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Foghorn Therapeutics (FHTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.